Able Laboratories (ABRX)

[Rawnoc]

Able Laboratories "buy," target price raised

Wednesday, November 03, 2004 9:41:54 AM ET
First Albany


NEW YORK, November 3 (newratings.com) - Analysts at First Albany reiterate their "buy" rating on Able Laboratories (ABRX.NAS). The target price has been raised from $25 to $27.

Most popular stories:
Advanced Micro Devices "market outperform," target price raised 11/15/04
MediGene "buy," fair value raised 11/15/04
Boeing unveils cargo 777 airplane model 11/15/04
Medco Health Solutions upgraded to "buy" 11/15/04
XCYTE Therapies upgraded to "outperform" - update 11/15/04
more...
In a research note published this morning, the analysts mention that the company reported its Q3 EPS marginally ahead of the estimates and the consensus. The upside during the quarter was driven by higher-than-expected sales from Able Laboratories' new products, the analysts say. The company is expected to file 15-to-20 ANDAs by 1H05, First Albany adds.